Market Place
Sourcing Support
Otsuka Showcases VOYXACT Data for IgAN at 2026 ISN Congress
25 Mar 2026 //
PHARMIWEB
Otsuka Seeks FDA Priority Review For Centanafadine In ADHD
27 Jan 2026 //
BUSINESSWIRE
GENESIS Pharma Partners With Otsuka For Donidalorsen
15 Dec 2025 //
PHARMIWEB
Otsuka, Lundbeck`s Rexulti snubbed by FDA in PTSD
22 Sep 2025 //
FIERCE PHARMA
US FDA Advisers Recommend Against Otsuka`s PTSD combination
21 Jul 2025 //
REUTERS
FDA Staff Raises Efficacy Concerns for Otsuka`s PTSD Combination
17 Jul 2025 //
FDA
Otsuka forms joint venture to boost IV solution supply
14 Nov 2024 //
FIERCE PHARMA
ICU Medical & Otsuka Announce Joint Venture to Boost IV in America
12 Nov 2024 //
PR NEWSWIRE
Otsuka tots up 6-figure unpaid salary for dementia caregivers
15 Oct 2024 //
FIERCE PHARMA
Aurinia Announces Japan Approval of LUPKYNIS® for Lupus Nephritis
24 Sep 2024 //
BUSINESSWIRE
Japan`s Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics
01 Aug 2024 //
PRESS RELEASE
UK partnership aims to support NHS use of depression app News
29 Jul 2024 //
PHARMAPHOROUM
Otsuka Announce FDA Acceptance of sNDA for Brexpiprazole and Sertraline
25 Jun 2024 //
BUSINESSWIRE
Otsuka mauled by ad body for `unacceptable` transparency failing
06 Jun 2024 //
FIERCE PHARMA
Otsuka, Lundbeck: Brexpiprazole Plus Sertraline Data In PTSD Presented
28 May 2024 //
BUSINESSWIRE
Otsuka to Terminate Development of AVP-786
22 May 2024 //
BUSINESSWIRE
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry
04 Apr 2024 //
BUSINESSWIRE
FDA clears Otsuka, Click`s prescription app for depression
03 Apr 2024 //
FIERCE BIOTECH
Otsuka and Click Thera Announce the FDA Clearance of Rejoyn for the MDD Symptoms
01 Apr 2024 //
BUSINESSWIRE
Otsuka and Lundbeck’s schizophrenia treatment gains EC approval
28 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI
18 Mar 2024 //
BUSINESSWIRE
Otsuka and Sumitomo Revise License Agreement
15 Mar 2024 //
PRESS RELEASE
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors
06 Mar 2024 //
PRESS RELEASE
Otsuka Pharma enters into $30 M investment contract with AN Venture Partners
29 Feb 2024 //
BIOSPECTRUM ASIA
Otsuka Pharmaceutical Launches "Kenkokeiei Tsunagaru Support ONLINE"
13 Feb 2024 //
PRESS RELEASE
Otsuka`s drug for Alzheimer`s disease agitation fails in late stage study
13 Feb 2024 //
BUSINESSWIRE
Novartis Obtains Approval for Pediatric Chronic Heart Failure for Angiotensin
09 Feb 2024 //
PRESS RELEASE
Otsuka and Jolly Good to Start Delivery of FACEDUO Content
08 Feb 2024 //
PRESS RELEASE
Otsuka Pharmaceutical Achieves "Silver" Level Certification
23 Jan 2024 //
PRESS RELEASE
Ionis announces European licensing agreement with Otsuka for donidalorsen
18 Dec 2023 //
PR NEWSWIRE
Otsuka Pharmaceutical Introduces New "Self-Care Leave" System
14 Dec 2023 //
PRESS RELEASE
D&I Award 2023 - Otsuka Pharmaceutical Designated as "Best Workplace"
13 Dec 2023 //
PRESS RELEASE
Pharmavite acquires Bonafide Health, a provider of women`s health products
01 Dec 2023 //
PRESS RELEASE
Otsuka Pharmaceutical to Sponsor Thematic Project "Resonance of Lives"
30 Nov 2023 //
PRESS RELEASE
Astex Has Third Approval Success in a Drug Discovery Collaboration
22 Nov 2023 //
PRESS RELEASE
Aurinia Announces Collaboration Partner Otsuka Filed NDA for LUPKYNIS
13 Nov 2023 //
BUSINESSWIRE
MIREVO® Obtains Regulatory Approval, a First in Japan
08 Nov 2023 //
PRESS RELEASE
US FDA approves Otsuka`s blood pressure treatment device for use
08 Nov 2023 //
REUTERS
Otsuka Pharmaceutical Granted Silver Certification in PRIDE Index 2023
07 Nov 2023 //
PRESS RELEASE
Otsuka Announces Personnel Changes
06 Nov 2023 //
PRESS RELEASE
Otsuka partners with former Olympic swimmer on kidney disease campaign
02 Nov 2023 //
ENDPTS
Otsuka reports positive results from two phase 3 trials of centanafadine
30 Oct 2023 //
PHARMABIZ
Otsuka Announces Positive Results From Phase 3 Trials of Centanafadine
27 Oct 2023 //
BUSINESSWIRE
Otsuka’s ADHD asset succeeds in registrational trials with children and teens
27 Oct 2023 //
ENDPTS
Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)
26 Oct 2023 //
PRESS RELEASE
Regulates moisture in the stratum corneum for skin care experience
03 Oct 2023 //
PRESS RELEASE
Otsuka and Astex announce that the European Commission has approved INAQOVI
19 Sep 2023 //
BUSINESSWIRE
Otsuka Enters into Agreement with Japan Association of Public Welfare Workers
15 Sep 2023 //
PRESS RELEASE
Otsuka pens AAV deal with Shape Therapeutics for eye gene therapies
08 Sep 2023 //
ENDPTS
Otsuka and Lundbeck Announce Results from Phase 3 Trials of Brexpiprazole
07 Sep 2023 //
PRESS RELEASE
Otsuka buys Mindset for CAD 80M to strengthen pipeline in neurological disorders
04 Sep 2023 //
BIOSPECTRUM ASIA
Otsuka Pharmaceutical to Acquire Mindset Pharma
01 Sep 2023 //
BIOSPACE
US FDA panel backs Otsuka`s blood pressure treatment device
22 Aug 2023 //
REUTERS
US FDA staff raise no concerns about Otsuka, Medtronic blood pressure devices
18 Aug 2023 //
REUTERS
Federal court judge rules in favor of Otsuka`s Taiho in Lonsurf patent suit
17 Aug 2023 //
ENDPTS
Astex Expands Drug Discovery Collaboration With MSD
09 Aug 2023 //
PRESS RELEASE
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
01 Aug 2023 //
BIOSPACE
Otsuka, Lundbeck`s campaign spotlights agitation symptoms in Alzheimer’s disease
26 Jul 2023 //
ENDPTS
Otsuka announces results of PIII trial showing reduced agitation in patients
27 Jun 2023 //
PRESS RELEASE
